Expertise in
30
conditions

Dr. Paul R. Conkling

Hematology | Oncology
Virginia Oncology Associates
1051 Loftis Blvd, Suite 100, 
Newport News, VA 
 (2344.1 mi)
Accepting New Patients
43 Years of Experience
Expertise in
30
conditions
Virginia Oncology Associates
1051 Loftis Blvd, Suite 100, 
Newport News, VA 
 (2344.1 mi)
OverviewInsuranceLocationsClinical Research

Overview

Paul Conkling is a Hematologist and an Oncologist in Newport News, Virginia. Dr. Conkling has been practicing medicine for over 43 years is highly rated in 30 conditions, according to our data. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Anal Cancer, and Non-Small Cell Lung Cancer (NSCLC). Dr. Conkling is currently accepting new patients.

His clinical research consists of co-authoring 30 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1982
Specialties
Hematology
Oncology
Licenses
Specialist in VA
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  Optima Health
  •  Humana
  •  Piedmont

Locations

VIRGINIA ONCOLOGY ASSOCIATES
1051 Loftis Blvd, Suite 100, Newport News, VA 23606

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Active_not_recruiting
Publish Date: February 03, 2025
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2025
Intervention Type: Drug
Study Drugs: LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor
Study Phase: Phase 1
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 1
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2024
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, IPI-549, Pegylated liposomal doxorubicin, Nab-paclitaxel
Study Phase: Phase 1
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Enrollment Status: Terminated
Publish Date: June 09, 2022
Intervention Type: Drug
Study Drugs: Trilaciclib, Topotecan
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

30 Total Publications

Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States.
Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States.
Journal: JCO clinical cancer informatics
Published: December 20, 2024
Similar Doctors
Expertise in
45
conditions
Dr. Michael Lee
Hematology | Oncology
Expertise in
45
conditions
Dr. Michael Lee
Hematology | Oncology

Virginia Oncology Associates

1950 Glenn Mitchell Dr, Suite 102, 
Virginia Beach, VA 
 (30.2 mi)
757-368-0437
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Lee is a Hematologist and an Oncologist in Virginia Beach, Virginia. Dr. Lee is highly rated in 45 conditions, according to our data. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

Expertise in
50
conditions
Dr. John F. Kessler
Hematology | Oncology
Expertise in
50
conditions
Dr. John F. Kessler
Hematology | Oncology

Virginia Oncology Associates

1051 Loftis Blvd, Suite 100, 
Newport News, VA 
757-873-9400
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Kessler is a Hematologist and an Oncologist in Newport News, Virginia. Dr. Kessler is highly rated in 50 conditions, according to our data. His top areas of expertise are Peripheral T-Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Breast Cancer, and Paget Disease of the Breast. Dr. Kessler is currently accepting new patients.

Expertise in
31
conditions
Dr. Burton F. Alexander
Hematology | Oncology
Expertise in
31
conditions
Dr. Burton F. Alexander
Hematology | Oncology

Virginia Oncology Associates

6251 E Virginia Beach Blvd, Suite 200, 
Norfolk, VA 
 (22.7 mi)
757-466-8683
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Burton Alexander is a Hematologist and an Oncologist in Norfolk, Virginia. Dr. Alexander is highly rated in 31 conditions, according to our data. His top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, Pulmonary Embolism, and Leukocytosis. Dr. Alexander is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile